HC Wainwright Analysts Raise Earnings Estimates for SGMO

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Equities researchers at HC Wainwright lifted their Q3 2025 earnings per share (EPS) estimates for Sangamo Therapeutics in a note issued to investors on Tuesday, August 12th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will earn $0.06 per share for the quarter, up from their prior estimate of ($0.08). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.02) EPS and FY2028 earnings at $0.15 EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. The business had revenue of $18.31 million during the quarter, compared to analyst estimates of $31.68 million.

SGMO has been the topic of a number of other reports. Barclays decreased their price objective on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, May 14th. Wall Street Zen raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.50.

Sangamo Therapeutics Stock Performance

SGMO opened at $0.58 on Friday. Sangamo Therapeutics has a one year low of $0.41 and a one year high of $3.18. The stock has a market capitalization of $174.99 million, a PE ratio of -2.00 and a beta of 1.18. The business’s 50 day moving average price is $0.52 and its 200 day moving average price is $0.71.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGMO. JPMorgan Chase & Co. raised its position in Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 21,793 shares during the period. R Squared Ltd purchased a new stake in Sangamo Therapeutics in the second quarter valued at approximately $28,000. Captrust Financial Advisors purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter worth $30,000. LPL Financial LLC increased its position in shares of Sangamo Therapeutics by 113.5% during the fourth quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 16,498 shares during the period. Finally, Cerity Partners LLC increased its position in shares of Sangamo Therapeutics by 439.2% during the first quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 44,800 shares during the period. Hedge funds and other institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.